ReCyte has 3 platform technologies with broad applications to therapy of vascular disorders:  (1) PureStem® library of clonal human embryonic progenitor cell lines (2) progenitor cell derivation methods for producing blood vessel and brown fat tissue progenitors with the aim of regenerating vasculature and cardioprotective brown fat, (3) progenitor cell secreted factors including microvesicles (exosomes) with aim of creating an “off the shelf” therapeutic product that is designed to promote tissue and organ regeneration.